Curebound, a philanthropic organization that funds groundbreaking cancer research, announces significant updates for its grant recipients.
The 2021 recipient of Curebound’s oncofertility Discovery Grant has secured $4.1 million in follow-on funding to expand clinical trials investigating fertility restoration in cancer patients. Additionally, one of the 2023 Cure Prize recipients has received $1.2 million to support clinical trials in pancreatic cancer research.
A 2023 Targeted Grant recipient has been recognized for developing a transformative AI precision-oncology platform that leverages artificial intelligence for accurate cancer diagnoses and treatment recommendations. This achievement is a testament to Curebound’s commitment to funding high-impact, innovative research.
Anne Marbarger, Curebound’s CEO, indicated that Curebound’s mission is to invest in bold ideas that have the potential to revolutionize cancer research and that they are proud to support these promising projects and their dedicated researchers.
Curebound’s grantmaking platform fosters collaboration among research institutions in San Diego, fostering partnerships that accelerate cancer detection, treatment, and cure advancements. The organization has awarded over $35 million in research grants, supporting 115 projects.
Curebound is committed to bringing innovative ideas to life and investing in research that has the potential to make a meaningful impact in the fight against cancer. By supporting the work of these talented researchers, Curebound aims to bring cures closer to reality.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
